Skin Symptoms of Lupus
Typical Cutaneous Manifestations
Lupus skin disease presents in four main specific patterns: malar ("butterfly") rash, discoid lesions, photosensitive rashes, and oral/mucosal ulcers, with many patients showing overlapping phenotypes rather than isolated presentations 1, 2.
Acute Cutaneous Lupus Erythematosus (ACLE)
- Malar rash: The classic "butterfly" distribution across cheeks and nasal bridge, sparing the nasolabial folds
- Generalized ACLE: Widespread erythematous patches on sun-exposed areas
- Strongly associated with active systemic disease and musculoskeletal symptoms 3
Subacute Cutaneous Lupus Erythematosus (SCLE)
- Annular (ring-shaped) or papulosquamous (scaly) plaques
- Predominantly affects upper back, shoulders, neck, and anterior chest
- Highly photosensitive
- Frequently associated with anti-Ro antibodies
- Can be medication-induced 3
Chronic Cutaneous Lupus Erythematosus (CCLE)
- Discoid lupus: Most common form with indurated, scaly plaques on scalp, face, and ears
- Causes permanent scarring, pigmentary changes, and scarring alopecia
- Less commonly: hyperkeratotic LE, lupus tumidus, lupus profundus, chilblain lupus 3
Mucosal Involvement
- Oral ulcers (typically painless)
- Nasal ulcers
- Present in approximately 50% of patients with active disease 4
Non-Specific Skin Findings
- Non-scarring alopecia
- Vasculitis
- Livedo reticularis
- Periungual telangiectasia
- Raynaud phenomenon 3
First-Line Management
Start with hydroxychloroquine (≤5 mg/kg real body weight) combined with topical corticosteroids or calcineurin inhibitors, plus strict photoprotection—this triple approach forms the foundation for all lupus skin disease 5.
Universal Baseline Measures
Hydroxychloroquine: Recommended for ALL lupus patients unless contraindicated, not exceeding 5 mg/kg real body weight 5
- Requires ophthalmological screening at baseline, after 5 years, then yearly 5
Photoprotection (mandatory):
- Avoid direct sun exposure, especially during high UV index days
- Physical barriers: wide-brimmed hats, sunglasses, long sleeves/pants
- Broad-spectrum sunscreen
- Assess vitamin D supplementation needs 6
Smoking cessation: Critical for treatment response 7
Topical Therapy
- Topical corticosteroids: First-line for localized lesions 5
- Calcineurin inhibitors (tacrolimus, pimecrolimus): Particularly valuable as steroid-sparing agents for facial skin to avoid steroid atrophy 5, 7
Systemic Therapy Algorithm
For patients not responding to topicals plus hydroxychloroquine, or requiring chronic glucocorticoids:
Step 1: Add immunomodulatory agents 5
- Methotrexate (strongest evidence)
- Mycophenolate
- Azathioprine
- Retinoids, dapsone (alternative options)
Step 2: For refractory cases requiring high-dose glucocorticoids 5
- Thalidomide/lenalidomide (moderate evidence but significant toxicity risk) 7
- Belimumab (moderate evidence for biologic therapy) 7
Glucocorticoid Strategy
- Can use systemic glucocorticoids initially based on severity 5
- Minimize to <7.5 mg/day prednisone equivalent for chronic use
- Withdraw when possible 5
- Pulse IV methylprednisolone (250-1000 mg for 1-3 days) for severe flares allows lower oral starting doses 5
Critical Pitfalls
The most common error is inadequate photoprotection counseling—UV exposure triggers both cutaneous and systemic flares, undermining all pharmacologic interventions 6. Patients must understand this is non-negotiable.
Second major pitfall: Prolonged high-dose glucocorticoid monotherapy without early introduction of steroid-sparing immunomodulatory agents, leading to cumulative toxicity and organ damage 5.
Third consideration: Approximately 70% of lupus patients have coexisting dermatologic conditions unrelated to lupus activity (including treatment complications), requiring comprehensive skin assessment beyond lupus-specific lesions 4.
The overlapping nature of cutaneous phenotypes (85% of patients show skin involvement during disease course, with 50% having active manifestations at any given time) means you cannot rely on a single "classic" presentation—most patients display multiple cutaneous patterns simultaneously 4, 2.